Core Viewpoint - TianTan Bio announced the completion of Phase I clinical trials for its "Recombinant Human Coagulation Factor VIII-Fc Fusion Protein," which is intended for the control and prevention of bleeding in patients with Hemophilia A [1] Company Summary - The product developed by Chengdu Rongsheng Pharmaceutical Co., Ltd., a subsidiary of TianTan Bio, is specifically designed for patients with Hemophilia A [1] - The clinical trial summary report has been obtained, indicating progress in the product's development [1] Industry Summary - The product is aimed at addressing bleeding control and prevention during surgeries for Hemophilia A patients, highlighting a significant advancement in treatment options within the hemophilia care sector [1] - It is important to note that the product is not suitable for treating von Willebrand disease, which may limit its market scope [1]